Is Stoke Therapeutics (STOK) Undervalued After Its Latest Earnings Losses?

Stoke Therapeutics (STOK) is back in focus after its third quarter 2026 earnings release, as investors weigh modest sales of US$11.26 million against a wider net loss of US$73.64 million.

The latest results have come after a choppy period for Stoke Therapeutics, with the share price falling 5.03% on the day of the release and down 15.63% year to date. Even so, the 1 year total shareholder return is 16.02%, and the 3 year total shareholder return is very large at around 5x, which signals long term holders have still seen strong gains despite more recent pressure.

Scan for other high-growth but loss-making biotechs at different stages of their journey by checking out 21 high quality undiscovered gems while you assess Stoke Therapeutics after this earnings shock.

Bulls see Stoke Therapeutics as a high potential genetic medicine platform repriced on short term losses. Bears see a small revenue base and widening net loss. Which story does the current valuation actually support?

Most Popular Narrative: 42% Undervalued

Stoke Therapeutics closed at $26.07 against a widely followed narrative fair value of $45.10. The gap between price and modelled potential is wide and firmly rooted in expectations for its genetic medicine platform.

The shift toward disease-modifying therapies in severe epilepsies raises the regulatory and evidentiary bar. Any delay, additional data requirements, or failure to show clear differentiation versus emerging competitors could push out potential launch timing and limit peak revenue.

See why 6 investors see Stoke Therapeutics as 42% undervalued.

Result: Fair Value of $45.10 (UNDERVALUED)

Still, the bullish Stoke Therapeutics story depends heavily on successful late stage Dravet data and on regulators not imposing extra trials or delays.

Find out about the key risks to this Stoke Therapeutics narrative.

Another View: Stoke Therapeutics Looks Expensive On Book Value

The first narrative focuses on future cash flows and long run earnings power. On a simpler yardstick, Stoke Therapeutics trades on a P/B of 4.8x, well above both the US Biotechs industry at 1.8x and its peer group at 2.1x. That kind of premium can amplify downside if the story disappoints. Which yardstick do you trust when sentiment swings next?

To see how that premium ties back to detailed valuation work, and whether the current price lines up with underlying fundamentals, See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Mixed signals like these rarely sit still for long, so it makes sense to move quickly, interrogate the data, and decide where Stoke Therapeutics fits in your portfolio. To weigh the tension between potential upside and the issues investors are worried about, start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Stoke Therapeutics?

Do not stop your research with Stoke Therapeutics. Broader idea generation can reveal opportunities that better match your risk tolerance, time horizon, and income needs.

• Target potential mispricing by scanning a curated 42 high quality undervalued stocks and see which businesses line up with the kind of upside you want to pursue.
• Build resilience into your holdings by reviewing a list of solid balance sheet and fundamentals (24 results) that can help you sidestep fragile businesses before trouble shows up in headlines.
• Boost your income options by checking a 6 dividend fortresses that focuses on companies combining meaningful yields with disciplined payout habits.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com